sur Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals and Curie.Bio Sign Research Agreement
Secarna Pharmaceuticals GmbH & Co. KG and a Curie.Bio portfolio company have entered into a research and option agreement. Announced on May 12, 2025, this collaboration aims to develop oligonucleotide therapeutics against an undisclosed target. Secarna will utilize its OligoCreator® platform, designed for rapid and safe therapeutic design.
Under the agreement, Secarna receives a technology access fee, research funding, and warrants for shares upon milestone achievement. This collaboration intends to advance treatment options for conditions currently difficult to treat with conventional methods. It combines Secarna's platform with Curie.Bio's drug discovery expertise.
Secarna's CEO, Konstantin Petropoulos, emphasized the potential to transform scientific innovation into life-changing therapies. This partnership may unlock new avenues for treating complex diseases, leveraging both companies' strengths.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Secarna Pharmaceuticals GmbH & Co. KG